Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

CALGB 9251 Regimen

A regimen comprised of a prephase (or cytoreductive phase), followed by two different chemotherapy regimens, given on an alternating schedule and… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
PURPOSE CALGB 49907 showed the superiority of standard therapy, which included either cyclophosphamide/doxorubicin (AC) or… Expand
Highly Cited
2015
Highly Cited
2015
PURPOSE We compared nab-paclitaxel or ixabepilone once per week to paclitaxel with bevacizumab as first-line therapy for patients… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
2015
2015
Taxane-based regimens are among the preferred first-line chemotherapy options for metastatic breast cancer, with weekly… Expand
2009
2009
LBA515 Background: I-SPY is a multi-center trial designed to identify predictive markers of pathological complete response (pCR… Expand
2009
2009
11009 Background: Effective treatment of breast cancer through the targeting of the HER2 protein in human breast cancer… Expand
2009
2009
CTRC-AACR San Antonio Breast Cancer Symposium: 2008 Abstracts Abstract #703 Background: The I-SPY trial is a multi… Expand
Review
2008
Review
2008
PURPOSE Retrospective data suggests prolonging the time to complete thoracic radiotherapy (TRT) may negatively impact tumor… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
Highly Cited
2004
Highly Cited
2004
3500 Background: Irinotecan prolongs survival in second line 5FU-refractory metastatic colorectal cancer (MCRC). First line… Expand
Highly Cited
2004
Highly Cited
2004
3500 Background: Irinotecan prolongs survival in second line 5FU-refractory metastatic colorectal cancer (MCRC). First line… Expand
2004
2004
4506 Background: A prostate-specific antigen (PSA) decline of > 50% is associated with a prolongation in survival for patients… Expand